Atara Biotherapeutics, Inc. (ATRA) Monday said its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting or PEW in patients with end stage renal disease or ESRD did not meet its primary endpoint.
The primary endpoint is defined as the percent change from baseline in Lean Body Mass as measured by Dual Energy X-Ray Absorptiometry at week 12 following weekly treatment with PINTA 745.
PINTA 745 also did not improve physical function, measures of glycemic control and markers of inflammation. There were no treatment related serious adverse events observed in the trial.
Atara Bio will now suspend further development of PINTA 745. To date, third-party direct costs for the development of PINTA 745 from inception through the third quarter of 2015 were about $10 million.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.